デフォルト表紙
市場調査レポート
商品コード
1008461

中枢神経系治療薬市場 - 成長、動向、COVID-19の影響、および予測(2021年~2026年)

Central Nervous System Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 120 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.27円
中枢神経系治療薬市場 - 成長、動向、COVID-19の影響、および予測(2021年~2026年)
出版日: 2021年05月13日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 120 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

中枢神経系(CNS)治療薬市場は、2021年から2026年の予測期間中、5.9%程度のCAGRとなると予測されています。

中枢神経系疾患に苦しむ患者数の増加は、中枢神経系治療薬市場の成長に貢献する重要な要因である可能性があります。WHOによると、脳卒中とアルツハイマー病は、2019年に世界で2番目と7番目に多い死因でした。さらに、ジェネリック医薬品の増加により、神経系医薬品の低中所得国への浸透が促進され、手頃な価格になると予想されます。またナノ粒子などのドラッグデリバリーシステムの革新は、新薬の機会を生み出します。これらの要因は、CNS治療薬市場の成長に貢献することが期待されます。

研究開発は複雑なプロセスであり、製薬業界における重要な決定です。これには、新薬の安全性と有効性の詳細な研究と、それらを市場にリリースする前の規制ガイドラインの遵守が含まれます。さらに、研究開発への支出は必ずしもより高いリターンをもたらすとは限らず、製薬企業がCNS治療薬に投資することを思いとどまらせる可能性があります。さらに、抗てんかん薬などの特定の中枢神経系薬について報告されている副作用は、市場全体の成長を阻害する可能性があります。

当レポートでは、世界の中枢神経系治療薬市場を調査し、市場の概要、市場の成長要因および阻害要因の分析、市場機会、地域別の市場規模の推移と予測、競合情勢、主要企業のプロファイルなどを提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概要
  • 市場の推進力
    • 中枢神経系障害の負担の上昇
    • ジェネリック医薬品の増加
    • 新規ドラッグデリバリーシステムの開発
  • 市場の抑制要因
    • CNS治療に関連する有害事象
    • 高い研究開発費
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • 病気別
    • 神経血管疾患
    • トラウマ
    • メンタルヘルス
    • 変性疾患
    • 感染症
    • その他
  • 医薬品クラス別
    • 鎮痛薬
    • 神経系薬
    • 麻酔薬
    • 抗パーキンソン薬
    • 抗てんかん
    • その他の医薬品クラス
  • 地域
    • 北米
    • 欧州
    • アジア太平洋
    • 中東とアフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Biogen
    • Otsuka Pharmaceutical Co. Ltd
    • Eli Lilly and Company
    • Merck KGaA
    • AstraZeneca
    • Takeda Pharmaceutical Coompany Limited
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd
    • Johnson &Johnson Private Limited
    • Pfizer Inc.
    • GlaxoSmithKline PLC

第7章 市場機会と動向

目次
Product Code: 71993

The central nervous system (CNS) therapeutics market is projected to register a CAGR of nearly 5.9% over the forecast period (2021 - 2026).

With the increasing COVID-19 cases, worldwide, healthcare services diverted all resources toward patients suffering from COVID-19 disease. Although COVID-19 severely affects the respiratory system, it has been reported to show effects on central and peripheral systems. These included encephalopathy, inflammation, ischaemic stroke, and peripheral neurological disorders. A research study published in JAMA Neurology involving 214 patients in China showed that patients with severe illness from COVID-19 had neurologic manifestations of acute cerebrovascular disease, impaired consciousness, and skeletal muscle injury. Additionally, clinical trials on the repurposing of anti-depressants for COVID-19 may have minimal impact on the CNS therapeutics market.

An increase in the number of patients suffering from CNS disease is likely to be the key factor contributing to the growth of the CNS therapeutics market. According to the WHO, in 2019, stroke and Alzheimer's are the second and seventh top-most causes for deaths, globally. A study published in The Lancet finds that neurological diseases are the third common cause of disability and premature deaths and are estimated to increase with age in Europe. Additionally, a rise in generics is expected to drive the penetration of neurologic drugs to lower and middle-income countries, making them affordable. Along with this, increasing awareness programs may result in drugs being easily accessible. Innovation in drug delivery systems, such as nanoparticles, creates opportunities for new drugs. A recent Rutgers research in 2020 was conducted for the treatment of neurological disorders, by creating a micro-environment and suppressing inflammation using nanomaterials, polymers, and neural proteins. Therefore, all the above factors are expected to contribute to the growth of the CNS therapeutics market.

R&D is a complex process and an important decision within the pharmaceutical industry. It involves a detailed study of the safety and efficacy of novel drugs, along with meeting regulatory guidelines before releasing them into the market. According to the analysis by Tufts Center for the Study of Drug Development in 2018, CNS drug development is 20% more time-consuming and takes 38% longer time to get approved than other non-CNS drugs. Moreover, expenditure in R&D may not always yield higher returns, making it a risky investment. As a result, drugs are priced higher to recover the spending. Hence, risky R&D spending for developing CNS drugs may discourage pharmaceutical companies from investing in CNS therapeutics. Furthermore, adverse reactions reported for certain CNS drugs, such as anti-epileptic drugs, may inhibit the overall market growth.

Key Market Trends

Degenerative Disease is Expected to Dominate the CNS Therapeutics Market over the Forecast Period

The degenerative disease segment occupies a major share of the market over the forecast period (2021 - 2026). This disease occurs when nerve cells in the brain and peripheral nervous systems lose their function and die. The major share of it is attributed to the increasing prevalence of Alzheimer's disease, Parkinson's disease, and multiple sclerosis.

According to the WHO, globally, 50 million people suffer from dementia, with nearly 60% living in low and middle-income countries. It estimates the number to reach 82 million by 2030. Atlas of MS shows that 2.8 million people live with multiple sclerosis worldwide and 10 million with Parkinson's disease as per the Parkinson's Foundation. The treatment options for these diseases are very few. Currently, five approved drugs are widely used for Alzheimer's, and 146 clinical studies are recruiting, which are in Phases 1, 2, and 3. Recently, FDA approved Ongentys capsules for Parkinson's disease when a patient's medications are not working well and Zeposia capsules for relapsing forms of multiple sclerosis. According to Alzheimer's Europe, it is estimated that about 7.8 million individuals in the European Union are with dementia. Furthermore, the Harvard NeuroDiscovery Center estimates that nearly 12 million Americans may suffer from neurodegenerative diseases 30 years from now if there are no measures taken. Therefore, the rise in prevalence of these diseases, drug development pipeline, and the potential of this segment opens opportunities for clinical studies, product launches, and strategic collaborations.

North America is Expected to Dominate the Central Nervous System Therapeutics Market

North America is expected to dominate the CNS therapeutics market over the forecast period (2021 - 2026).

According to GBD 2019, neurological disorders ranked third for the cause of deaths in Canada and fourth in the United States. The Alzheimer's Disease Fact and Figures Report estimated that 5.8 million Americans are living with dementia, among which 5.6 million are aged 65 years and above in 2019. The same source also reports that the total costs for Alzheimer's were USD 290 billion, which includes Medicare (51%), Medicaid (17%), Out of Pocket (22%), and other costs (11%).

Government funding and support for research activities are increasing due to the rising burden of the disease. The US congress invested about USD 10 million in multiple sclerosis research and may increase the funding by USD 20 million. CDC established a National Neurological Conditions Surveillance System (NNCSS) for tracking the disease. In 2019, Canada released its first national strategy for tackling dementia. The Canadian Institutes of Health Research spent around USD 200 million for research activities on dementia, and it is providing an additional USD 31.6 million over 5 years, which is likely to bring together individuals for advanced research opportunities. A large number of clinical studies are undergoing in North America, especially in the United States. Among the total neurological disease clinical studies being conducted, worldwide, more than half are in the United States. In March 2021, US President Biden signed the American Rescue Plan Act 2021. According to the act, a portion of spending is allotted to mental health services, further increasing the government activities toward neurological diseases. The rising burden of the disease and healthcare infrastructure and supportive government initiatives make North America a very attractive opportunity for industries.

Competitive Landscape

The central nervous system therapeutics market remains moderately competitive, with key players in the market. However, the need for innovation in the treatment and drug delivery system and clinical trials and strategic collaboration is likely to help companies maintain their market position. Some of the major players include Biogen Inc, Otsuka Pharmaceutical Co. Ltd, Eli Lilly and Company, Merck & Co., AstraZeneca, Takeda Pharmaceutical Company Limited, Novartis AG, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Private Limited, Pfizer Inc., and GlaxoSmithKline PLC.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Burden of CNS Disorders
    • 4.2.2 Increase in Generic Drugs
    • 4.2.3 Development of Novel Drug Delivery Systems
  • 4.3 Market Restraints
    • 4.3.1 Adverse Events Associated with CNS Therapeutics
    • 4.3.2 High R&D Costs
  • 4.4 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Buyers/Consumers
    • 4.4.2 Bargaining Power of Suppliers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Disease
    • 5.1.1 Neurovascular Diseases
    • 5.1.2 Trauma
    • 5.1.3 Mental Health
      • 5.1.3.1 Anxiety Disorders
      • 5.1.3.2 Epilepsy
      • 5.1.3.3 Psychotic Disorders
      • 5.1.3.4 Others
    • 5.1.4 Degenerative Diseases
      • 5.1.4.1 Alzheimer's Disease
      • 5.1.4.2 Parkinson's Disease
      • 5.1.4.3 Multiple Sclerosis
      • 5.1.4.4 Amyotrophic Lateral Sclerosis
      • 5.1.4.5 Others
    • 5.1.5 Infectious Diseases
    • 5.1.6 Cancer
    • 5.1.7 Others
  • 5.2 By Drug Class
    • 5.2.1 Analgesics
    • 5.2.2 Nervous System Drugs
    • 5.2.3 Anesthetics
    • 5.2.4 Anti-Parkinson Drugs
    • 5.2.5 Anti-Epileptics
    • 5.2.6 Other Drug Classes
  • 5.3 By Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Biogen
    • 6.1.2 Otsuka Pharmaceutical Co. Ltd
    • 6.1.3 Eli Lilly and Company
    • 6.1.4 Merck KGaA
    • 6.1.5 AstraZeneca
    • 6.1.6 Takeda Pharmaceutical Coompany Limited
    • 6.1.7 Novartis AG
    • 6.1.8 Teva Pharmaceutical Industries Ltd
    • 6.1.9 Johnson & Johnson Private Limited
    • 6.1.10 Pfizer Inc.
    • 6.1.11 GlaxoSmithKline PLC

7 MARKET OPPORTUNITIES AND FUTURE TRENDS